Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 01, 2023

Decrease in Natalizumab Drug Levels After Switching From Intravenous to Subcutaneous Administration

Journal of Neurology, Neurosurgery, and Psychiatry


Additional Info

Journal of Neurology, Neurosurgery, and Psychiatry
Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis
J. Neurol. Neurosurg. Psychiatr. 2023 Jan 13;[EPub Ahead of Print], AA Toorop, ZLE van Kempen, M Steenhuis, J Nielsen, LGF Sinnige, G van Dijk, CM Roosendaal, EPJ Arnoldus, E Hoitsma, BI Lissenberg-Witte, BA de Jong, BWV Oosten, EMM Strijbis, BMJ Uitdehaag, T Rispens, J Killestein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading